Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Rhea-AI Summary

Coherus Oncology (NASDAQ:CHRS) reported Q2 2025 financial results, highlighting $10.0 million in LOQTORZI net revenue, a 36% increase from Q1 2025. The company ended Q2 with $238 million in cash and completed the UDENYCA divestiture for $483.4 million, with potential milestone payments of up to $75 million.

Key pipeline developments include progress on CHS-114, a cytolytic CCR8 antibody, and casdozokitug, a first-in-class IL-27 antagonist, with data readouts expected in 1H 2026. The company reported a Q2 net loss from continuing operations of $44.9 million ($0.39 per share), while net income from discontinued operations was $342.6 million ($2.95 per share), primarily due to the UDENYCA divestiture gain.

Positive

• LOQTORZI revenue grew 36% quarter-over-quarter to $10.0 million
• Strong cash position of $238 million, providing runway through 2026
• Completed UDENYCA divestiture for $483.4 million with potential additional $75 million in milestones
• LOQTORZI received preferred status in NCCN guidelines for NPC indication

Negative

• Net loss from continuing operations of $44.9 million in Q2 2025
• Increased R&D expenses to $26.3 million, up from $20.6 million year-over-year
• Significant accrued rebates and fees of $96.8 million to be settled through 2026
• Total revenue from continuing operations remained flat year-over-year at $10.3 million

Insights

Biotech Financial Analyst

Coherus showed 36% QoQ LOQTORZI growth with solid cash position after UDENYCA divestiture, positioning for key 2026 pipeline catalysts.

Coherus Oncology's Q2 results reveal a company in transition, pivoting from its biosimilar business to a focused oncology player. LOQTORZI's $10.0 million revenue represents 36% sequential growth from Q1, indicating strong commercial traction for their nasopharyngeal carcinoma treatment. The 163% year-over-year growth ($10.0M vs $3.8M in Q2 2024) is impressive, though from a low base.

The company's financial position has dramatically strengthened following the UDENYCA divestiture, which yielded $483.4 million in cash. This strategic decision allowed Coherus to eliminate substantial debt by paying off $230 million in convertible notes and a $47.7 million royalty obligation. The $238 million cash position now provides runway through 2026, importantly covering the company through upcoming clinical readouts.

Despite revenue growth, operating expenses remain substantial with R&D at $26.3 million and SG&A at $26.0 million, resulting in a $44.9 million net loss from continuing operations. The non-GAAP loss of $39.0 million ($0.34 per share) actually worsened compared to $34.7 million in Q2 2024, indicating the commercial operation hasn't yet reached scale.

The near-term investor focus will be on LOQTORZI's commercial trajectory, particularly after receiving preferred status in NCCN guidelines. However, the longer-term value proposition hinges on pipeline assets - specifically CHS-114 (CCR8 antibody) and casdozokitug (IL-27 antagonist), both with data readouts in 1H 2026. These assets represent significant potential value drivers if successful, targeting sizable markets across multiple solid tumors.

The $96.8 million in accrued rebates and fees that remain Coherus's responsibility post-divestiture represent a significant cash outflow over the coming quarters that investors should monitor. While the cash position appears strong, these legacy obligations will impact free cash flow in the near term.

Oncology Drug Development Expert

Coherus's pipeline shows promising mechanism combinations, with critical 2026 readouts potentially validating CCR8 targeting as a major cancer therapy approach.

The strategic focus on LOQTORZI as both a commercial product and development platform is scientifically sound. As a PD-1 inhibitor with differentiated properties, LOQTORZI provides Coherus a foundation for combination studies with their novel pipeline agents targeting complementary immune pathways.

CHS-114 represents one of the most intriguing approaches in immuno-oncology today. As a cytolytic CCR8 antibody, it specifically depletes regulatory T cells (Tregs) within the tumor microenvironment without affecting peripheral Tregs essential for immune homeostasis. This selective depletion addresses a key mechanism of tumor immune evasion. The mechanistic rationale for combining Treg depletion via CHS-114 with T-cell activation via LOQTORZI (anti-PD-1) is compelling - essentially removing the brakes (Tregs) while simultaneously pressing the accelerator (PD-1 blockade) on anti-tumor immunity.

The company's clinical development strategy targets tumor types with significant unmet needs - 2L head and neck cancer, gastric cancer, and esophageal squamous cell carcinoma - where immunotherapy approaches have shown promise but with substantial room for improvement. These indications represent pragmatic choices for demonstrating efficacy signals.

Casdozokitug, targeting IL-27, represents another novel approach in immuno-oncology. IL-27 is a cytokine with predominantly immunosuppressive effects in the tumor microenvironment, and early clinical data showing monotherapy activity in treatment-refractory NSCLC and ccRCC is noteworthy. The triple combination with LOQTORZI and bevacizumab in hepatocellular carcinoma could potentially address multiple aspects of tumor biology: immune suppression, T-cell exhaustion, and angiogenesis.

The 1H 2026 data readouts will be pivotal in determining whether these mechanistic approaches translate to meaningful clinical benefit. If successful, particularly for CHS-114, Coherus could validate CCR8 as a major therapeutic target across multiple solid tumors, potentially establishing a new cornerstone of cancer immunotherapy.

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 –

– Data readouts for CHS-114 and casdozokitug on track for 1H 2026 –

– Q2 2025 ending cash, cash equivalents and marketable securities of $238 million –

– Conference call today at 5:00 p.m. Eastern Time –

REDWOOD CITY, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the second quarter ended June 30, 2025 and provided an overview of recent business highlights.

“Coherus Oncology is dedicated to significantly extending survival for people with cancer,” said Denny Lanfear, Coherus Chairman and Chief Executive Officer. “We are executing well commercially, and our focus on maximizing LOQTORZI’s potential in nasopharyngeal carcinoma has resulted in a 36% net revenue increase over Q1 2025 to $10.0 million. With a cash runway through 2026, beyond key data readouts, continued strong clinical execution will derisk the pipeline, unlocking large U.S. market potential and creating Ex-U.S. licensing opportunities as the clinical data further evolve.”

“Our pipeline clinical programs with CHS-114 and casdozkitug in solid tumors are progressing and on track for data readouts in 2026,” said Theresa LaVallee, Ph.D., Coherus Chief Scientific and Development Officer. “Data on CHS-114, our cytolytic CCR8 antibody, in combination with toripalimab, provide compelling evidence of their potential in remodeling the tumor microenvironment by depleting immunosuppressive Treg cells with CHS-114 and boosting immune activation with toripalimab. We believe that in 2026, anti-CCR8s may start to realize their therapeutic promise and become a new treatment backbone, used broadly across solid tumor types.”

RECENT BUSINESS HIGHLIGHTS  

LOQTORZI^® (toripalimab-tpzi) COMMERCIAL UPDATES

• LOQTORZI is the only FDA-approved and available treatment in the U.S. for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC), in all patient subsets and across all lines of therapy.
• LOQTORZI net revenue for Q2 2025 was $10.0 million, a 36% growth over LOQTORZI net revenue of $7.3 million in Q1 2025. This growth was driven largely by higher patient demand and some inventory restocking. LOQTORZI net revenue was $3.8 million in Q2 2024.
• Following a recent revision in the National Comprehensive Cancer Network (NCCN) guidelines granting LOQTORZI preferred status for NPC indication, the Company has seen strong demand growth among Head & Neck cancer specialists. The Company’s focus remains on deepening adoption within the community oncologist setting. 

ADVANCEMENT OF INNOVATIVE, NEXT-GENERATION ONCOLOGY PIPELINE 

LOQTORZI is a next-generation, differentiated PD-1 marketed in the U.S. in two indications.

• Coherus plans to maximize the value of this medicine by combining LOQTORZI with internal pipeline candidates, CHS-114 and casdozokitug, for additional solid tumor indications and entering into capital-efficient external partnerships for label expansions.
  

CHS-114 is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding.

• Phase 1b CHS-114/toripalimab combination dose optimization studies in 2L head and neck (HNSCC) and 2L gastric cancers are underway, with initial data readouts expected in 1H 2026.
• A Phase 1b study evaluating the CHS-114/toripalimab combination, with and without chemotherapy, in 1L and 2L esophageal squamous cell carcinoma (ESCC), respectively, is underway with a first data readout expected in 1H 2026.

Casdozokitug is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory non-small cell lung cancer (NSCLC) and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).

• Enrollment is ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with the first data readout expected in 1H 2026.
  

UDENYCA DIVESTITURE COMPLETED AND CERTAIN FINANCIAL OBLIGATIONS PAID OFF

On April 11, 2025, Coherus completed the UDENYCA divestiture and received $483.4 million in cash, inclusive of $118.4 million for UDENYCA product inventory. In addition, the Company is eligible to receive potential milestone payments of up to $75 million.

During Q2 2025, the Company used a portion of the proceeds from the UDENYCA sale to: (1) repay substantially all of the $230 million aggregate principal amount of the outstanding 2026 Convertible Notes, and (2) buy out the royalty rights on the net revenues of UDENYCA, in accordance with the Revenue Purchase and Sale Agreement, resulting in a $47.7 million payment.

SECOND QUARTER 2025 FINANCIAL RESULTS

Net revenue from continuing operations was approximately $10.3 million for each of the quarters ended June 30, 2025 and 2024. LOQTORZI net product revenue increased $6.2 million compared to Q2 in the prior year primarily due to volume growth, offset by a $6.2 million decrease in other revenue primarily due to the upfront fee recognized in the prior year period for the outlicense of rights to commercialize toripalimab within Canada. Net revenue was $17.9 million and $12.6 million for the six months ended June 30, 2025 and 2024, respectively, with the increase primarily driven by volume growth of LOQTORZI, which launched in December 2023.

Cost of goods sold (COGS) from continuing operations was $3.4 million and $1.8 million during the three months ended June 30, 2025 and 2024, respectively, and $6.0 million and $3.2 million during the six months ended June 30, 2025 and 2024, respectively. The increases were primarily due to volume growth of LOQTORZI.

Research and development (R&D) expenses from continuing operations were $26.3 million and $20.6 million for the three months ended June 30, 2025 and 2024, respectively, and $50.7 million and $49.0 million during the six months ended June 30, 2025 and 2024, respectively. The increases were primarily due to increased costs for development of casdozokitug and CHS-114, partially offset by reductions in co-development costs for toripalimab, termination of the TIGIT Program, savings from reduced headcount, and lower infrastructure costs.

Selling, general and administrative (SG&A) expenses from continuing operations were $26.0 million and $27.5 million during the three months ended June 30, 2025 and 2024, respectively, and $52.1 million and $67.7 million during the six months ended June 30, 2025 and 2024, respectively. The decreases were driven primarily by lower headcount and decreased operating costs following Coherus’ recent divestitures. The decrease in the six-month period was also due to a net $6.8 million charge in the first quarter of 2024 for the write-off of an intangible asset and associated contingent value right liability related to NZV930, which was acquired in the Surface Oncology, Inc. acquisition.

Interest expense from continuing operations was $2.3 million and $4.1 million during the three months ended June 30, 2025 and 2024, respectively, and $4.4 million and $7.2 million during the six months ended June 30, 2025 and 2024, respectively. The decreases were primarily due to the prepayment of the remaining $75.0 million of the principal amount due under the 2027 Term Loans on May 8, 2024, partially offset by interest on the $38.7 million senior secured term loan facility and the LOQTORZI portion of the Revenue Participation Right Purchase and Sale Agreement, each commencing May 8, 2024.

Net loss from continuing operations for the second quarter of 2025 was $44.9 million, or $(0.39) per share on a diluted basis, compared to a net loss of $54.9 million, or $(0.48) per share on a diluted basis, for the same period in 2024. Net loss for the first half of 2025 was $92.3 million, or $(0.80) per share on a diluted basis, compared to a net loss of $122.9 million, or $(1.08) per share on a diluted basis for the first half of 2024.

Non-GAAP net loss from continuing operations for the second quarter of 2025 was $39.0 million, or $(0.34) per share on a diluted basis, compared to $34.7 million, or $(0.30) per share for the same period in 2024. Non-GAAP net loss for the first half of 2025 was $79.9 million, or $(0.69) per share on a diluted basis, compared to $88.3 million, or $(0.78) per share for the first half of 2024. See “Non-GAAP Financial Measures” below for a discussion on how Coherus calculates non-GAAP net loss from continuing operations and a reconciliation to the most directly comparable GAAP measures.

Net income from discontinued operations, net of tax was $342.6 million, or $2.95 per share on a diluted basis, for the second quarter of 2025 compared to $41.9 million, or $0.37 per share on a diluted basis, for the same period in 2024. Net income from discontinued operations, net of tax for the first half of 2025 was $333.5 million, or $2.88 per share on a diluted basis, compared to $212.8 million, or $1.87 per share on a diluted basis for the same period in 2024.

The increases compared to the prior year periods were primarily due to the $339.1 million net gain on the UDENYCA divestiture in April 2025, partially offset by the $22.9 million net gain on the YUSIMRY Sale in June 2024, the $10.3 million charge for loss on debt extinguishment, and lower net revenue driven by the 2024 divestitures. Total net revenues attributable to the Company’s divested products, UDENYCA, CIMERLI and YUSIMRY, which are reflected in discontinued operations, were $23.1 million and $54.7 million for the three months ended June 30, 2025 and 2024, respectively, and $55.2 million and $129.4 million during the six months ended June 30, 2025 and 2024, respectively.

The increase in the six-month period was partially offset by $153.6 million gain on sale of the CIMERLI divestiture in the first quarter of 2024 and an $11.8 million charge in the first quarter of 2025 for the change in fair value of the Royalty Fee Derivative Liability related to UDENYCA.

Cash, cash equivalents and marketable securities totaled $237.6 million as of June 30, 2025, compared to $126.0 million as of December 31, 2024. A majority of the $96.8 million in accrued rebates, fees and reserves reflected on the June 30, 2025 balance sheet were UDENYCA-related obligations that did not transfer in the divestiture and are expected to be settled in a front-loaded fashion over the remainder of the year and into 2026.

Conference Call Information
When: Thursday, August 7, 2025, starting at 5:00 p.m. Eastern Daylight Time

To access the conference call:

• TOLL-FREE DIAL-IN: (800) 715-9871
• INTERNATIONAL DIAL-IN: (646) 307-1963
• Conference ID 8712736
  

Webcast: https://edge.media-server.com/mmc/p/skv7e6d2

A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.

Please dial in 15 minutes early to ensure a timely connection to the call.

About Coherus Oncology 

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI^® (toripalimab-tpzi), growing revenues and a promising proprietary pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. The Company’s strategy is to grow sales of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both their pipeline candidates as well as its partners, driving sales multiples and synergies from proprietary combinations.

Coherus’ immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in multiple Phase 1/2 and Phase 2 studies in patients with advanced solid tumors, including NSCLC and HCC. CHS-114 is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b studies in patients with advanced solid tumors, including HNSCC, gastric cancer, and esophageal cancer.

For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus’ expectations about identifying sales multiples and synergies; the ability of Coherus’ I-O pipeline to enhance outcomes for cancer patients; projections for cash runway; the ability to reduce risk for Coherus’ pipeline; Coherus’ ability to receive the potential milestone payments related to the divestiture of its UDENYCA franchise; expectations for the timing when Coherus will be able to commence future clinical studies or receive clinical data for its product candidates; Coherus’ ability to enter into additional partnerships; Coherus’ ability to grow revenues; and Coherus’ expectations about total addressable opportunity for each of its product candidates.

Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to Coherus’ dependence on an ability to raise funds in the future, which may not be available on acceptable terms or at all; risks related to Coherus’ existing and potential collaboration partners; risks of Coherus’ competitive position; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of Coherus’ regulatory filings; the risk of FDA review issues; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2025 filed with the Securities and Exchange Commission on or about the date of this press release, including the section therein captioned “Risk Factors” and in other documents Coherus files with the Securities and Exchange Commission. Coherus’ results for the fiscal quarter ended June 30, 2025 are not necessarily indicative of its operating results for any future periods. 

LOQTORZI^®, whether or not appearing in large print or with the trademark symbol, is a registered trademark of Coherus Oncology, Inc.
©2025 Coherus Oncology, Inc. All rights reserved.

Coherus Contact Information:

For Investors & Media:
Jodi Sievers
VP, Investor Relations & Corporate Communications
IR@coherus.com

Coherus Oncology, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited)
		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2025				2024				2025				2024
Net revenue		$	10,254			$	10,296			$	17,853			$	12,604
Costs and expenses:
Cost of goods sold			3,395				1,809				6,048				3,248
Research and development			26,306				20,598				50,662				49,022
Selling, general and administrative			26,039				27,515				52,064				67,747
Total costs and expenses			55,740				49,922				108,774				120,017
Loss from operations			(45,486	)			(39,626	)			(90,921	)			(107,413	)
Interest expense			(2,277	)			(4,062	)			(4,427	)			(7,180	)
Loss on debt extinguishment			—				(12,630	)			—				(12,630	)
Other income (expense), net			2,901				1,467				3,088				4,336
Loss from continuing operations before income taxes			(44,862	)			(54,851	)			(92,260	)			(122,887	)
Income tax provision			—				—				—				—
Net loss from continuing operations			(44,862	)			(54,851	)			(92,260	)			(122,887	)
Net income from discontinued operations, net of tax			342,629				41,930				333,458				212,841
Net income (loss)		$	297,767			$	(12,921	)		$	241,198			$	89,954
Net income (loss) per share:
Net loss from continuing operations - basic and diluted		$	(0.39	)		$	(0.48	)		$	(0.80	)		$	(1.08	)
Net income from discontinued operations - basic and diluted		$	2.95			$	0.37			$	2.88			$	1.87
Net income (loss) per share - basic and diluted		$	2.57			$	(0.11	)		$	2.08			$	0.79
Weighted-average number of shares used in computing net income (loss) per share:
Basic and diluted			116,077,710				114,819,965				115,968,352				113,784,636

Coherus Oncology, Inc. Condensed Consolidated Balance Sheets (in thousands) (unaudited)
		June 30,			December 31,
		2025			2024
Assets
Cash and cash equivalents		$	216,893		$	125,987
Investments in marketable securities			20,744			—
Trade receivables, net			5,109			111,324
TSA receivables, net			114,530			11,010
Inventory			4,513			4,207
Intangible assets, net			52,312			53,646
Other assets			25,363			25,936
Assets of discontinued operations			—			116,423
Total assets		$	439,464		$	448,533
Liabilities and Stockholders’ Equity (Deficit)
Accrued rebates, fees and reserve		$	96,814		$	164,867
TSA payables and other accrued liabilities			103,999			11,026
Term loan			36,867			36,698
Convertible notes			121			228,229
Other liabilities			81,836			139,703
Total stockholders' equity (deficit)			119,827			(131,990	)
Total liabilities and stockholders’ equity (deficit)		$	439,464		$	448,533

Coherus Oncology, Inc. Condensed Consolidated Statements of Cash Flows (in thousands) (unaudited)
		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2025				2024				2025				2024
Cash, cash equivalents and restricted cash at beginning of the period		$	82,674			$	260,227			$	126,250			$	103,343
Net cash (used in) provided by operating activities			(46,632	)			59,734				(72,458	)			12,968
Purchases of investments in marketable securities			(20,726	)			—				(20,726	)			—
Proceeds from maturities of investments in marketable securities			—				—				—				6,200
Proceeds from sale of investments in marketable securities			—				—				—				8,688
Net cash received related to the Sale Transactions			483,400				40,000				478,681				227,823
Milestone payment to Junshi Biosciences			—				(12,500	)			(12,500	)			(12,500	)
Other investing activities, net			(36	)			156				(303	)			208
Net cash provided by investing activities			462,638				27,656				445,152				230,419
Proceeds from 2029 Term loan, net of debt discount & issuance costs			—				37,120				—				37,120
Proceeds from (repayment of) Revenue Purchase and Sale Agreement, net of issuance costs			(47,652	)			36,495				(47,652	)			36,495
Proceeds from issuance of common stock under ATM Offering, net of issuance costs			—				(52	)			—				1,455
Proceeds from purchase under the employee stock purchase plan			188				685				188				685
Taxes paid related to net share settlement			(16	)			(1,711	)			(280	)			(2,456	)
Redemption of 2026 Convertible Notes, including transaction costs			(233,185	)			—				(233,185	)			—
Repayment of 2027 Term Loans, premiums and fees			—				(260,387	)			—				(260,387	)
Other financing activities, net			(859	)			(75	)			(859	)			50
Net cash used in financing activities			(281,524	)			(187,925	)			(281,788	)			(187,038	)
Net increase (decrease) in cash, cash equivalents and restricted cash			134,482				(100,535	)			90,906				56,349
Cash, cash equivalents and restricted cash at end of the period		$	217,156			$	159,692			$	217,156			$	159,692
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents		$	216,893			$	159,240			$	216,893			$	159,240
Restricted cash balance			263				452				263				452
Cash, cash equivalents and restricted cash		$	217,156			$	159,692			$	217,156			$	159,692

Non-GAAP Financial Measures

To supplement the financial results presented in accordance with GAAP, Coherus has also included in this press release non-GAAP net loss from continuing operations, and the related per share measures, which exclude from net loss from continuing operations, and the related per share measures, stock-based compensation expense, amortization of intangible assets, loss on debt extinguishment, impairments of intangible assets, and change in fair value of our Royalty Fee Derivative Liability. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. Coherus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand Coherus’ business.

Coherus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, Coherus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Coherus’ results from period to period, and to identify operating trends in Coherus’ business. Coherus also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.

Coherus Oncology, Inc. Reconciliation of GAAP Net Loss from Continuing Operations to Non-GAAP Net Loss from Continuing Operations (in thousands, except share and per share data) (unaudited)
		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2025				2024				2025				2024
GAAP net loss from continuing operations		$	(44,862	)		$	(54,851	)		$	(92,260	)		$	(122,887	)
Adjustments:
Stock-based compensation expense			5,166				6,859				10,212				13,675
Loss on debt extinguishment			—				12,630				—				12,630
Impairment of out-license asset and remeasurement of CVR liability, net			—				—				—				6,772
Change in fair value of Royalty Fee Derivative Liability			—				—				810				—
Amortization of intangible assets			667				679				1,334				1,542
Non-GAAP net loss from continuing operations		$	(39,029	)		$	(34,683	)		$	(79,904	)		$	(88,268	)
GAAP
Net loss per share from continuing operations, basic and diluted		$	(0.39	)		$	(0.48	)		$	(0.80	)		$	(1.08	)
Shares used in computing basic and diluted net loss per share			116,077,710				114,819,965				115,968,352				113,784,636
Non-GAAP
Net loss per share from continuing operations, basic and diluted		$	(0.34	)		$	(0.30	)		$	(0.69	)		$	(0.78	)
Shares used in computing basic and diluted net loss per share			116,077,710				114,819,965				115,968,352				113,784,636

FAQ

What was Coherus (CHRS) Q2 2025 LOQTORZI revenue?

LOQTORZI net revenue was $10.0 million in Q2 2025, representing a 36% increase from Q1 2025's $7.3 million, driven by higher patient demand and inventory restocking.

How much did Coherus receive from the UDENYCA divestiture in 2025?

Coherus received $483.4 million in cash, including $118.4 million for UDENYCA inventory, plus potential milestone payments of up to $75 million.

What is Coherus (CHRS) cash position after Q2 2025?

Coherus ended Q2 2025 with $237.6 million in cash, cash equivalents and marketable securities, up from $126.0 million at the end of 2024.

When will Coherus report data for CHS-114 and casdozokitug?

Coherus expects to report initial data readouts for both CHS-114 and casdozokitug in first half of 2026.

What was Coherus (CHRS) net loss in Q2 2025?

Coherus reported a net loss from continuing operations of $44.9 million ($0.39 per share) in Q2 2025, while posting net income from discontinued operations of $342.6 million ($2.95 per share).